Soteria Biotherapeutics, Inc., a San Francisco, CA-based immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, raised $42m in Series A financing.
The round was led by Roche Venture Fund and 5AM Ventures with participation from other leading investors, including M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
The company intends to use the funds for advancement of its technology and build a pipeline of T-LITE development candidates with potential in well validated cancer targets.
Led by Kristine Ball, chief executive officer, Soteria is developing a next generation of switchable bispecific T-cell engagers to treat cancer patients with solid tumors. The company’s T-LITETM platform provides small molecule-dependent activation of bispecific antibody therapies, enabling treatments through pulsatile activity, reduced side effects and higher dosing.
Soteria was founded in 2018 with technology licensed from UC San Francisco.
The team of founders, management and board members includes:
- Kristine Ball, Chief Executive Officer and Member of the Board
- Zachary Hill, PhD, Co-Founder and SVP, Chief Scientific Officer, and Member of the Board
- Mohammad Tabrizi, PhD, VP Preclinical Development
- Alex Martinko, PhD, Co-Founder and Senior Director of Protein Science
- Jim Wells, PhD, Academic Co-founder, Chair of Scientific Advisory Board, and Professor of Pharmaceutical Chemistry at UC San Francisco
- Steven P. James, Board Chair and Chief Executive Officer of Pionyr Immunotherapeutics
- David Allison, PhD, Member of the Board and Partner at 5AM Ventures
- Keno Gutierrez, PhD, Member of the Board and Vice President at M Ventures
- Nisha Marathe, PhD, Member of the Board and Investment Director at Roche Venture Fund
- David Morris, MD, Member of the Board and Operating Partner at Novartis Venture Fund
- Momo Wu, PhD, Member of the Board and Portfolio Investment Manager at Emerson Collective